Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation

Myocardial dysfunction is a common complication during sepsis and significantly contributes to the mortality of patients with septic shock. However, none of the available therapeutic strategies proven to be effective in patients with severe sepsis are designed specifically to target myocardial dysfu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International immunopharmacology 2012-11, Vol.14 (3), p.243-251
Hauptverfasser: Cao, Wenjuan, Wang, Yuan, Lv, Xiuxiu, Yu, Xiaohui, Li, Xiaojian, Li, Hongmei, Wang, Yanping, Lu, Daxiang, Qi, Renbin, Wang, Huadong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 251
container_issue 3
container_start_page 243
container_title International immunopharmacology
container_volume 14
creator Cao, Wenjuan
Wang, Yuan
Lv, Xiuxiu
Yu, Xiaohui
Li, Xiaojian
Li, Hongmei
Wang, Yanping
Lu, Daxiang
Qi, Renbin
Wang, Huadong
description Myocardial dysfunction is a common complication during sepsis and significantly contributes to the mortality of patients with septic shock. However, none of the available therapeutic strategies proven to be effective in patients with severe sepsis are designed specifically to target myocardial dysfunction. The purpose of the present study is to investigate the effect of rhynchophylline (Rhy) on LPS-induced myocardial dysfunction in mice. We found that pretreatment with Rhy significantly improved cardiac systolic dysfunction, increased stroke volume and cardiac output in mice challenged with LPS. LPS induced cardiac inhibitor-κBα (I-κBα) phosphorylation, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) mRNA expression, and in turn increased cardiac TNF-α and IL-1β protein production, all of which were attenuated by pretreatment with Rhy. Immunohistochemistry revealed that TNF-α was found in infiltrated macrophages (F4/80+) and myocardium, and Rhy reduced TNF-α immunostaining in cardiac infiltrated macrophages in LPS-challenged mice. Furthermore, Rhy inhibited LPS-induced I-κBα phosphorylation and TNF-α production in cultured mouse peritoneal macrophages, but not in neonatal mouse cardiomyocytes. Pretreatment with Rhy significantly decreased the mortality of LPS-challenged mice. These results indicate that Rhy reduces cardiac dysfunction and improves survival via suppression of macrophage I-κBα phosphorylation in LPS-challenged mice, and suggest that Rhy may be a potential agent for the treatment of septic cardiac dysfunction. [Display omitted] ► Rhynchophylline inhibited LPS-induced I-κBα phosphorylation in macrophages. ► Rhynchophylline did not block LPS-induced TNF-α production in cardiomyocytes. ► Rhynchophylline inhibited LPS-induced cardiac I-κBα phosphorylation. ► Rhynchophylline inhibited LPS-induced cardiac TNF-α and IL-1β expression. ► Rhynchophylline improved cardiac dysfunction and survival in LPS-challenged mice.
doi_str_mv 10.1016/j.intimp.2012.07.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1081872913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576912002196</els_id><sourcerecordid>1081872913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-427da4ca8f4b1826bef859c9ec3f16513178e39388382c5a75ec9cd788eeea6e3</originalsourceid><addsrcrecordid>eNp9kc-K1TAUxosozh99A5FsBDetSds06UbQQceBAUF0HXJPTm9zSdOatIU-i0_h1oeYZzKXe9Wdi3BC-H3nOzlflr1gtGCUNW8OhfWzHaaipKwsqCgoo4-ySyaFzJmg_HG680bkXDTtRXYV44HS9F6zp9lFWcqa8YpfZj--9JuHfpz6zTnrkUwBV_RzJKCDsRqI2WK3eJjt6In2hiTLMK4YSVzCalftiPXE2WmcRrdFDdDrYA3mqTqHfo-GDBaQrFYnyZT6x2j9ngwaQrLVeyR3-cOv9w8_ydSPMZ2wOX20e5Y96bSL-Pxcr7NvHz98vfmU33--vbt5d59D1ZZzXpfC6Bq07Oodk2Wzw07yFlqEqmMNZxUTEqu2krKSJXAtOEILRkiJiLrB6jp7feqbPvZ9wTirwUZA57THcYmKUZm2WrasSmh9QtPsMQbs1BTsoMOWIHWMRR3UKRZ1jEVRoVIsSfby7LDsBjR_RX9ySMCrM6AjaNcF7cHGf1zDE9gcG709cZj2sVoMKoJFD2hsQJiVGe3_J_kNrv-0SA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1081872913</pqid></control><display><type>article</type><title>Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cao, Wenjuan ; Wang, Yuan ; Lv, Xiuxiu ; Yu, Xiaohui ; Li, Xiaojian ; Li, Hongmei ; Wang, Yanping ; Lu, Daxiang ; Qi, Renbin ; Wang, Huadong</creator><creatorcontrib>Cao, Wenjuan ; Wang, Yuan ; Lv, Xiuxiu ; Yu, Xiaohui ; Li, Xiaojian ; Li, Hongmei ; Wang, Yanping ; Lu, Daxiang ; Qi, Renbin ; Wang, Huadong</creatorcontrib><description>Myocardial dysfunction is a common complication during sepsis and significantly contributes to the mortality of patients with septic shock. However, none of the available therapeutic strategies proven to be effective in patients with severe sepsis are designed specifically to target myocardial dysfunction. The purpose of the present study is to investigate the effect of rhynchophylline (Rhy) on LPS-induced myocardial dysfunction in mice. We found that pretreatment with Rhy significantly improved cardiac systolic dysfunction, increased stroke volume and cardiac output in mice challenged with LPS. LPS induced cardiac inhibitor-κBα (I-κBα) phosphorylation, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) mRNA expression, and in turn increased cardiac TNF-α and IL-1β protein production, all of which were attenuated by pretreatment with Rhy. Immunohistochemistry revealed that TNF-α was found in infiltrated macrophages (F4/80+) and myocardium, and Rhy reduced TNF-α immunostaining in cardiac infiltrated macrophages in LPS-challenged mice. Furthermore, Rhy inhibited LPS-induced I-κBα phosphorylation and TNF-α production in cultured mouse peritoneal macrophages, but not in neonatal mouse cardiomyocytes. Pretreatment with Rhy significantly decreased the mortality of LPS-challenged mice. These results indicate that Rhy reduces cardiac dysfunction and improves survival via suppression of macrophage I-κBα phosphorylation in LPS-challenged mice, and suggest that Rhy may be a potential agent for the treatment of septic cardiac dysfunction. [Display omitted] ► Rhynchophylline inhibited LPS-induced I-κBα phosphorylation in macrophages. ► Rhynchophylline did not block LPS-induced TNF-α production in cardiomyocytes. ► Rhynchophylline inhibited LPS-induced cardiac I-κBα phosphorylation. ► Rhynchophylline inhibited LPS-induced cardiac TNF-α and IL-1β expression. ► Rhynchophylline improved cardiac dysfunction and survival in LPS-challenged mice.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2012.07.010</identifier><identifier>PMID: 22841535</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Animals ; Animals, Newborn ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiomyopathies - drug therapy ; Cardiomyopathies - metabolism ; Cardiomyopathies - physiopathology ; Cardiotonic Agents - pharmacology ; Cardiotonic Agents - therapeutic use ; Heart ; Heart - drug effects ; Heart - physiopathology ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; I-kappa B Proteins - antagonists &amp; inhibitors ; Indole Alkaloids - pharmacology ; Indole Alkaloids - therapeutic use ; Inhibitor-κBα ; Interleukin-1beta - genetics ; Interleukin-1beta - metabolism ; Lipopolysaccharide ; Lipopolysaccharides ; Macrophages, Peritoneal - metabolism ; Male ; Medical sciences ; Mice ; Myocardial dysfunction ; Myocardium - metabolism ; NF-KappaB Inhibitor alpha ; Pharmacology. Drug treatments ; Rhynchophylline ; RNA, Messenger - metabolism ; Tumor Necrosis Factor-alpha - genetics ; Tumor Necrosis Factor-alpha - metabolism</subject><ispartof>International immunopharmacology, 2012-11, Vol.14 (3), p.243-251</ispartof><rights>2012 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-427da4ca8f4b1826bef859c9ec3f16513178e39388382c5a75ec9cd788eeea6e3</citedby><cites>FETCH-LOGICAL-c392t-427da4ca8f4b1826bef859c9ec3f16513178e39388382c5a75ec9cd788eeea6e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2012.07.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26584160$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22841535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cao, Wenjuan</creatorcontrib><creatorcontrib>Wang, Yuan</creatorcontrib><creatorcontrib>Lv, Xiuxiu</creatorcontrib><creatorcontrib>Yu, Xiaohui</creatorcontrib><creatorcontrib>Li, Xiaojian</creatorcontrib><creatorcontrib>Li, Hongmei</creatorcontrib><creatorcontrib>Wang, Yanping</creatorcontrib><creatorcontrib>Lu, Daxiang</creatorcontrib><creatorcontrib>Qi, Renbin</creatorcontrib><creatorcontrib>Wang, Huadong</creatorcontrib><title>Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>Myocardial dysfunction is a common complication during sepsis and significantly contributes to the mortality of patients with septic shock. However, none of the available therapeutic strategies proven to be effective in patients with severe sepsis are designed specifically to target myocardial dysfunction. The purpose of the present study is to investigate the effect of rhynchophylline (Rhy) on LPS-induced myocardial dysfunction in mice. We found that pretreatment with Rhy significantly improved cardiac systolic dysfunction, increased stroke volume and cardiac output in mice challenged with LPS. LPS induced cardiac inhibitor-κBα (I-κBα) phosphorylation, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) mRNA expression, and in turn increased cardiac TNF-α and IL-1β protein production, all of which were attenuated by pretreatment with Rhy. Immunohistochemistry revealed that TNF-α was found in infiltrated macrophages (F4/80+) and myocardium, and Rhy reduced TNF-α immunostaining in cardiac infiltrated macrophages in LPS-challenged mice. Furthermore, Rhy inhibited LPS-induced I-κBα phosphorylation and TNF-α production in cultured mouse peritoneal macrophages, but not in neonatal mouse cardiomyocytes. Pretreatment with Rhy significantly decreased the mortality of LPS-challenged mice. These results indicate that Rhy reduces cardiac dysfunction and improves survival via suppression of macrophage I-κBα phosphorylation in LPS-challenged mice, and suggest that Rhy may be a potential agent for the treatment of septic cardiac dysfunction. [Display omitted] ► Rhynchophylline inhibited LPS-induced I-κBα phosphorylation in macrophages. ► Rhynchophylline did not block LPS-induced TNF-α production in cardiomyocytes. ► Rhynchophylline inhibited LPS-induced cardiac I-κBα phosphorylation. ► Rhynchophylline inhibited LPS-induced cardiac TNF-α and IL-1β expression. ► Rhynchophylline improved cardiac dysfunction and survival in LPS-challenged mice.</description><subject>Animals</subject><subject>Animals, Newborn</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomyopathies - drug therapy</subject><subject>Cardiomyopathies - metabolism</subject><subject>Cardiomyopathies - physiopathology</subject><subject>Cardiotonic Agents - pharmacology</subject><subject>Cardiotonic Agents - therapeutic use</subject><subject>Heart</subject><subject>Heart - drug effects</subject><subject>Heart - physiopathology</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>I-kappa B Proteins - antagonists &amp; inhibitors</subject><subject>Indole Alkaloids - pharmacology</subject><subject>Indole Alkaloids - therapeutic use</subject><subject>Inhibitor-κBα</subject><subject>Interleukin-1beta - genetics</subject><subject>Interleukin-1beta - metabolism</subject><subject>Lipopolysaccharide</subject><subject>Lipopolysaccharides</subject><subject>Macrophages, Peritoneal - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Myocardial dysfunction</subject><subject>Myocardium - metabolism</subject><subject>NF-KappaB Inhibitor alpha</subject><subject>Pharmacology. Drug treatments</subject><subject>Rhynchophylline</subject><subject>RNA, Messenger - metabolism</subject><subject>Tumor Necrosis Factor-alpha - genetics</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc-K1TAUxosozh99A5FsBDetSds06UbQQceBAUF0HXJPTm9zSdOatIU-i0_h1oeYZzKXe9Wdi3BC-H3nOzlflr1gtGCUNW8OhfWzHaaipKwsqCgoo4-ySyaFzJmg_HG680bkXDTtRXYV44HS9F6zp9lFWcqa8YpfZj--9JuHfpz6zTnrkUwBV_RzJKCDsRqI2WK3eJjt6In2hiTLMK4YSVzCalftiPXE2WmcRrdFDdDrYA3mqTqHfo-GDBaQrFYnyZT6x2j9ngwaQrLVeyR3-cOv9w8_ydSPMZ2wOX20e5Y96bSL-Pxcr7NvHz98vfmU33--vbt5d59D1ZZzXpfC6Bq07Oodk2Wzw07yFlqEqmMNZxUTEqu2krKSJXAtOEILRkiJiLrB6jp7feqbPvZ9wTirwUZA57THcYmKUZm2WrasSmh9QtPsMQbs1BTsoMOWIHWMRR3UKRZ1jEVRoVIsSfby7LDsBjR_RX9ySMCrM6AjaNcF7cHGf1zDE9gcG709cZj2sVoMKoJFD2hsQJiVGe3_J_kNrv-0SA</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>Cao, Wenjuan</creator><creator>Wang, Yuan</creator><creator>Lv, Xiuxiu</creator><creator>Yu, Xiaohui</creator><creator>Li, Xiaojian</creator><creator>Li, Hongmei</creator><creator>Wang, Yanping</creator><creator>Lu, Daxiang</creator><creator>Qi, Renbin</creator><creator>Wang, Huadong</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121101</creationdate><title>Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation</title><author>Cao, Wenjuan ; Wang, Yuan ; Lv, Xiuxiu ; Yu, Xiaohui ; Li, Xiaojian ; Li, Hongmei ; Wang, Yanping ; Lu, Daxiang ; Qi, Renbin ; Wang, Huadong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-427da4ca8f4b1826bef859c9ec3f16513178e39388382c5a75ec9cd788eeea6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Animals, Newborn</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomyopathies - drug therapy</topic><topic>Cardiomyopathies - metabolism</topic><topic>Cardiomyopathies - physiopathology</topic><topic>Cardiotonic Agents - pharmacology</topic><topic>Cardiotonic Agents - therapeutic use</topic><topic>Heart</topic><topic>Heart - drug effects</topic><topic>Heart - physiopathology</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>I-kappa B Proteins - antagonists &amp; inhibitors</topic><topic>Indole Alkaloids - pharmacology</topic><topic>Indole Alkaloids - therapeutic use</topic><topic>Inhibitor-κBα</topic><topic>Interleukin-1beta - genetics</topic><topic>Interleukin-1beta - metabolism</topic><topic>Lipopolysaccharide</topic><topic>Lipopolysaccharides</topic><topic>Macrophages, Peritoneal - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Myocardial dysfunction</topic><topic>Myocardium - metabolism</topic><topic>NF-KappaB Inhibitor alpha</topic><topic>Pharmacology. Drug treatments</topic><topic>Rhynchophylline</topic><topic>RNA, Messenger - metabolism</topic><topic>Tumor Necrosis Factor-alpha - genetics</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, Wenjuan</creatorcontrib><creatorcontrib>Wang, Yuan</creatorcontrib><creatorcontrib>Lv, Xiuxiu</creatorcontrib><creatorcontrib>Yu, Xiaohui</creatorcontrib><creatorcontrib>Li, Xiaojian</creatorcontrib><creatorcontrib>Li, Hongmei</creatorcontrib><creatorcontrib>Wang, Yanping</creatorcontrib><creatorcontrib>Lu, Daxiang</creatorcontrib><creatorcontrib>Qi, Renbin</creatorcontrib><creatorcontrib>Wang, Huadong</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, Wenjuan</au><au>Wang, Yuan</au><au>Lv, Xiuxiu</au><au>Yu, Xiaohui</au><au>Li, Xiaojian</au><au>Li, Hongmei</au><au>Wang, Yanping</au><au>Lu, Daxiang</au><au>Qi, Renbin</au><au>Wang, Huadong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>14</volume><issue>3</issue><spage>243</spage><epage>251</epage><pages>243-251</pages><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>Myocardial dysfunction is a common complication during sepsis and significantly contributes to the mortality of patients with septic shock. However, none of the available therapeutic strategies proven to be effective in patients with severe sepsis are designed specifically to target myocardial dysfunction. The purpose of the present study is to investigate the effect of rhynchophylline (Rhy) on LPS-induced myocardial dysfunction in mice. We found that pretreatment with Rhy significantly improved cardiac systolic dysfunction, increased stroke volume and cardiac output in mice challenged with LPS. LPS induced cardiac inhibitor-κBα (I-κBα) phosphorylation, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) mRNA expression, and in turn increased cardiac TNF-α and IL-1β protein production, all of which were attenuated by pretreatment with Rhy. Immunohistochemistry revealed that TNF-α was found in infiltrated macrophages (F4/80+) and myocardium, and Rhy reduced TNF-α immunostaining in cardiac infiltrated macrophages in LPS-challenged mice. Furthermore, Rhy inhibited LPS-induced I-κBα phosphorylation and TNF-α production in cultured mouse peritoneal macrophages, but not in neonatal mouse cardiomyocytes. Pretreatment with Rhy significantly decreased the mortality of LPS-challenged mice. These results indicate that Rhy reduces cardiac dysfunction and improves survival via suppression of macrophage I-κBα phosphorylation in LPS-challenged mice, and suggest that Rhy may be a potential agent for the treatment of septic cardiac dysfunction. [Display omitted] ► Rhynchophylline inhibited LPS-induced I-κBα phosphorylation in macrophages. ► Rhynchophylline did not block LPS-induced TNF-α production in cardiomyocytes. ► Rhynchophylline inhibited LPS-induced cardiac I-κBα phosphorylation. ► Rhynchophylline inhibited LPS-induced cardiac TNF-α and IL-1β expression. ► Rhynchophylline improved cardiac dysfunction and survival in LPS-challenged mice.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>22841535</pmid><doi>10.1016/j.intimp.2012.07.010</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1567-5769
ispartof International immunopharmacology, 2012-11, Vol.14 (3), p.243-251
issn 1567-5769
1878-1705
language eng
recordid cdi_proquest_miscellaneous_1081872913
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Animals, Newborn
Biological and medical sciences
Cardiology. Vascular system
Cardiomyopathies - drug therapy
Cardiomyopathies - metabolism
Cardiomyopathies - physiopathology
Cardiotonic Agents - pharmacology
Cardiotonic Agents - therapeutic use
Heart
Heart - drug effects
Heart - physiopathology
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
I-kappa B Proteins - antagonists & inhibitors
Indole Alkaloids - pharmacology
Indole Alkaloids - therapeutic use
Inhibitor-κBα
Interleukin-1beta - genetics
Interleukin-1beta - metabolism
Lipopolysaccharide
Lipopolysaccharides
Macrophages, Peritoneal - metabolism
Male
Medical sciences
Mice
Myocardial dysfunction
Myocardium - metabolism
NF-KappaB Inhibitor alpha
Pharmacology. Drug treatments
Rhynchophylline
RNA, Messenger - metabolism
Tumor Necrosis Factor-alpha - genetics
Tumor Necrosis Factor-alpha - metabolism
title Rhynchophylline prevents cardiac dysfunction and improves survival in lipopolysaccharide-challenged mice via suppressing macrophage I-κBα phosphorylation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A42%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rhynchophylline%20prevents%20cardiac%20dysfunction%20and%20improves%20survival%20in%20lipopolysaccharide-challenged%20mice%20via%20suppressing%20macrophage%20I-%CE%BAB%CE%B1%20phosphorylation&rft.jtitle=International%20immunopharmacology&rft.au=Cao,%20Wenjuan&rft.date=2012-11-01&rft.volume=14&rft.issue=3&rft.spage=243&rft.epage=251&rft.pages=243-251&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2012.07.010&rft_dat=%3Cproquest_cross%3E1081872913%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1081872913&rft_id=info:pmid/22841535&rft_els_id=S1567576912002196&rfr_iscdi=true